Quarterly ResultMay 13, 2026, 07:02 AM
PDS Biotech Amends Phase 3 Trial for Accelerated Approval; Q1 Net Loss $7.3M
AI Summary
PDS Biotechnology provided a business and clinical programs update and reported Q1 2026 financial results. The company amended its VERSATILE-003 Phase 3 trial protocol to include progression-free survival as an interim primary endpoint, potentially creating an accelerated approval pathway for PDS0101 in HPV16-positive head and neck cancer. Positive clinical data for PDS01ADC in metastatic colorectal cancer and encouraging early results in metastatic castration-resistant prostate cancer were also published. For Q1 2026, the net loss decreased to $7.3 million, or $0.13 per share, from $8.5 million in Q1 2025.
Key Highlights
- VERSATILE-003 Phase 3 trial protocol amended for potential accelerated approval pathway for PDS0101.
- PDS01ADC in mCRC showed 77.8% objective response rate and 85% 24-month survival rate.
- PDS01ADC in mCRPC showed 9.6 months median PFS and 40% median PSA decline.
- New patents granted for PDS0101 in the U.S. and Japan, extending market protection into the 2040s.
- Q1 2026 net loss was $7.3 million, or $0.13 per share, down from $8.5 million in Q1 2025.
- Research and development expenses decreased to $3.5 million from $5.8 million year-over-year.
- General and administrative expenses decreased to $3.1 million from $3.3 million year-over-year.
- Cash and cash equivalents stood at $21.7 million as of March 31, 2026.